According to media reports, Mindray Medical, the leading medical device company, will soon re-report the IPO of the GEM. Mindray Medical is one of the benchmarks for the privatization of A shares in China. In March 2016, Mindray Medical's privatization transaction price was US$3.3 billion, and the value of the new round of financing in 2017 was approximately US$56 billion.
The industry said that the policy will increase support for the "four new" enterprises, and guide Baidu, Tencent and other "unicorn" companies to return to A shares, creating conditions for the rapid listing of giants or unicorn companies A shares. Mindray Medical products cover life information and support, in vitro diagnostic equipment and medical imaging. It has developed a number of “China's No. 1†products, breaking the long-term monopoly of foreign countries in China. In 2016, the revenue scale was 9 billion and the profit scale was as high as 17 Billion is the absolute giant of the medical device industry . The IPO Fast Track Policy may speed up the listing process of Mindray and related companies are concerned.
In addition to direct participation in mass transit, Shenzhen Energy Investment Co., Ltd. Shenzhen Venture Capital holds approximately 4.56 million shares of Mindray. Boya Bio's controlling shareholder Gao Tejia holds 7 million shares of Mindray. Jiuqiang Bio and Mindray signed an OEM framework cooperation agreement.
Yancheng Rongtai Labware Co.,Ltd , https://www.rongtailab.com